A phase Ib/II study evaluating safety and efficacy of NKTR-214 in combination with entinostat in patients with metastatic melanoma who have previously progressed on treatment with an anti-PD-1 (programmed death receptor-1) agent
Phase of Trial: Phase I/II
Latest Information Update: 05 Nov 2018
Price : $35 *
At a glance
- Drugs Bempegaldesleukin (Primary) ; Entinostat (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms ENCORE 606
- Sponsors Syndax Pharmaceuticals
- 05 Nov 2018 According to a Syndax Pharmaceuticals media release, this trial is expected to begin enrolling patients in the second quarter of 2019.
- 07 Aug 2018 According to a Syndax Pharmaceuticals media release, this trial is expected to begin enrolling patients in the first half of 2019.
- 05 Jun 2018 New trial record